402 related articles for article (PubMed ID: 32700072)
41. New and emerging therapies for acute myeloid leukaemia.
Davis JR; Benjamin DJ; Jonas BA
J Investig Med; 2018 Dec; 66(8):1088-1095. PubMed ID: 30127098
[TBL] [Abstract][Full Text] [Related]
42. [What is recommended in the treatment of acute myeloid leukemia?].
Thol F
Internist (Berl); 2019 Dec; 60(12):1240-1250. PubMed ID: 31690995
[TBL] [Abstract][Full Text] [Related]
43. Pharmacoeconomic considerations for acute myeloid leukemia pharmacotherapy.
Marchetti M; Albertin L; Limberti G; Canicattì M
Expert Opin Pharmacother; 2022 Feb; 23(2):263-272. PubMed ID: 34886738
[TBL] [Abstract][Full Text] [Related]
44. Intensified-Dose Chemotherapy in Combination With Gemtuzumab-Ozogamicin for the Treatment of Favorable-Risk Acute Myeloid Leukemia (AML).
Vegunta R; Harel R; Steinberg A
Cureus; 2022 Jun; 14(6):e26240. PubMed ID: 35898381
[TBL] [Abstract][Full Text] [Related]
45. Treatment of Relapsed/Refractory Acute Myeloid Leukemia.
Bose P; Vachhani P; Cortes JE
Curr Treat Options Oncol; 2017 Mar; 18(3):17. PubMed ID: 28286924
[TBL] [Abstract][Full Text] [Related]
46. Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia.
Bross PF; Beitz J; Chen G; Chen XH; Duffy E; Kieffer L; Roy S; Sridhara R; Rahman A; Williams G; Pazdur R
Clin Cancer Res; 2001 Jun; 7(6):1490-6. PubMed ID: 11410481
[TBL] [Abstract][Full Text] [Related]
47. Which novel agents hold the greatest promise in AML?
DiNardo CD
Best Pract Res Clin Haematol; 2019 Dec; 32(4):101106. PubMed ID: 31779980
[TBL] [Abstract][Full Text] [Related]
48. New Therapeutic Strategies for Adult Acute Myeloid Leukemia.
Ishii H; Yano S
Cancers (Basel); 2022 Jun; 14(11):. PubMed ID: 35681786
[TBL] [Abstract][Full Text] [Related]
49. Progress in acute myeloid leukaemia: small molecular inhibitors with small benefits.
Hilal T
Ecancermedicalscience; 2020; 14():1015. PubMed ID: 32256698
[TBL] [Abstract][Full Text] [Related]
50. Resistance to targeted therapies in acute myeloid leukemia.
Mecklenbrauck R; Heuser M
Clin Exp Metastasis; 2023 Feb; 40(1):33-44. PubMed ID: 36318439
[TBL] [Abstract][Full Text] [Related]
51. Management of Acute Myeloid Leukemia (AML) in Older Patients.
Abdallah M; Xie Z; Ready A; Manogna D; Mendler JH; Loh KP
Curr Oncol Rep; 2020 Jul; 22(10):103. PubMed ID: 32725515
[TBL] [Abstract][Full Text] [Related]
52. Treatment options for acute myeloid leukemia patients aged <60 years.
Visani G; Chiarucci M; Paolasini S; Loscocco F; Isidori A
Front Oncol; 2022; 12():897220. PubMed ID: 36276074
[TBL] [Abstract][Full Text] [Related]
53. A concise review of BCL-2 inhibition in acute myeloid leukemia.
Yogarajah M; Stone RM
Expert Rev Hematol; 2018 Feb; 11(2):145-154. PubMed ID: 29264938
[TBL] [Abstract][Full Text] [Related]
54. Refining AML Treatment: The Role of Genetics in Response and Resistance Evaluation to New Agents.
Halik A; Arends CM; Bullinger L; Damm F; Frick M
Cancers (Basel); 2022 Mar; 14(7):. PubMed ID: 35406464
[TBL] [Abstract][Full Text] [Related]
55. New Food and Drug Administration-Approved and Emerging Novel Treatment Options for Acute Myeloid Leukemia.
Click ZR; Seddon AN; Bae YR; Fisher JD; Ogunniyi A
Pharmacotherapy; 2018 Nov; 38(11):1143-1154. PubMed ID: 30220082
[TBL] [Abstract][Full Text] [Related]
56. FDA Approval Summary: Mylotarg for Treatment of Patients with Relapsed or Refractory CD33-Positive Acute Myeloid Leukemia.
Norsworthy KJ; Ko CW; Lee JE; Liu J; John CS; Przepiorka D; Farrell AT; Pazdur R
Oncologist; 2018 Sep; 23(9):1103-1108. PubMed ID: 29650683
[TBL] [Abstract][Full Text] [Related]
57. Nursing implications of mylotarg: a novel antibody-targeted chemotherapy for CD33+ acute myeloid leukemia in first relapse.
Shannon-Dorcy K
Oncol Nurs Forum; 2002 May; 29(4):E52-9. PubMed ID: 12011919
[TBL] [Abstract][Full Text] [Related]
58. Gemtuzumab ozogamicin for the treatment of acute myeloid leukemia.
Baron J; Wang ES
Expert Rev Clin Pharmacol; 2018 Jun; 11(6):549-559. PubMed ID: 29787320
[TBL] [Abstract][Full Text] [Related]
59. Case report of combination therapy with Azacytidine, Enasidenib and Venetoclax in primary refractory AML.
Jasra S; Kazemi M; Shah N; Chen J; Fehn K; Wang Y; Mantzaris I; Kornblum N; Sica A; Bachier L; Goldfinger M; Gritsman K; Braunschweig I; Steidl U; Shastri A; Verma A
Exp Hematol Oncol; 2021 Jan; 10(1):1. PubMed ID: 33397455
[TBL] [Abstract][Full Text] [Related]
60. Reformulating acute myeloid leukemia: liposomal cytarabine and daunorubicin (CPX-351) as an emerging therapy for secondary AML.
Chen EC; Fathi AT; Brunner AM
Onco Targets Ther; 2018; 11():3425-3434. PubMed ID: 29928134
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
